Ziftomenib
CAS 2134675-36-6Small Molecule
Overview
Ziftomenib is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL5095038).
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Ziftomenib expires 16 Jul 2044 and exclusivity 13 Nov 2030. Generic API sourcing typically opens up once these lapse.
Chemical identity
- IUPAC name
- 4-methyl-5-[[4-[[2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]piperidin-1-yl]methyl]-1-[(2S)-2-(4-methylsulfonylpiperazin-1-yl)propyl]indole-2-carbonitrile
- Canonical SMILES
- CC1=C(C=CC2=C1C=C(N2C[C@H](C)N3CCN(CC3)S(=O)(=O)C)C#N)CN4CCC(CC4)NC5=C6C=C(SC6=NC(=N5)NC)CC(F)(F)F
- InChIKey
- BGGALFIXXQOTPY-NRFANRHFSA-N
Verified Supplier Partner
Do you supply Ziftomenib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.